Audiological monitoring of cisplatin exposed patients;Monitoramento da audição de pacientes expostos à cisplatina

Revista Brasileira de Otorrinolaringologia

Volumn 69, Issue 2, 2003, Pages 215-221

  Garcia, Adriana P ^a,c   Iório, Maria Cecília M ^a   Petrilli, Antônio S ^a,b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Departamento de Pediatria

^c NONE   (Brazil)

Author keywords

Audiometry; Cisplatin; Hearing

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; IFOSFAMIDE;

AMPLITUDE MODULATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUDIOLOGY; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; DISTORTION PRODUCT OTOACOUSTIC EMISSION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EXPOSURE; DRUG INDUCED DISEASE; EARLY DIAGNOSIS; EVALUATION; HEARING LOSS; HUMAN; OSTEOSARCOMA; OTOTOXICITY; PROSPECTIVE STUDY; PURE TONE AUDIOMETRY; SPEECH INTELLIGIBILITY;

EID: 12444290858     PISSN: 00347299     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0034-72992003000200011     Document Type: Article

References (25)

1. Schweitzer VG. Ototoxicity of Chemotherapic Agents. Otolaryngol Clin North Am 1993;26 (5):759-789.
2. Ruiz L, Gilden J, Jaffe N, Robertson R & Wang YM. Auditory Function in Pediatric Ostesarcoma Patients Treated with Multiple Doses of cis-Diamminedichloroplatinum (II). Cancer Res 1989;49:742-44.
3. Fausti SA, Henry JA, Schaeffer HI, Olson DJ, Frey RH & Bagby GC. High-Frequency Monitoring for Early Detection of Cisplatin Ototoxicity. Arch Otolaryngol Head Neck Surg 1993;119:661-666.
4. Pasic TR & Dobie RA. Cis-Platinum Ototoxicity in Children. Laryngoscope 1991;101:985-991.
5. Dishtchekenian A, Iório MCM, Petrilli AS & Azevedo MF. Monitorização Auditiva na Ototoxicidade. In: Barros APB, Arakawa L, Tonini MD & Carvalho VA. Fonoaudiologia em Cancerologia. Fundação Oncocentro de São Paulo - Comitê de Fonoaudiologia em Cancerologia; 2000. p. 260-269.
6. nd American Academy of Audiology Annual Convention. Chicago; 2000. p. 146.
7. Dreschler WA, VD Hulst RJAM, Tange RA & Urbanus NAM. Role of High-Frequency Audiometry in Early Detection of Ototoxicity. Audiology 1989;28:211-220.
8. Laurell G & Jungnelius U. High-Dose Cisplatin Treatment: Hearing Loss and Plasma Concentrations. Laryngoscope 1990;100:724-734.
9. Brock PR, Bellman SC, Yeomans EC, Pinkerton CR & Pritchard J. Cisplatin Ototoxicity in Children: a Practical Grading System. Med Pediatr Oncol 1991;19:295-300.
10. Link MP & Eilber F. Osteosarcoma. In: Pizzo, P.A. & Poplack, D.G. Principles and Practice of Pediatric Oncology. 3(rd) edition. Philadelphia: Lippincott Raven Publishers; 1997. p. 889-920.
11. Macedo CR & Petrilli AS. Tumores Ósseos Malignos na Criança e no Adolescente. Pediatr Mod 1999;35 (8):600-608.
12. American National Standard Institute - American National Standards Specification for Audiometers, American Standard, S3.6, 1969.
13. Kopelman J, Budnick AS, Sessions RB, Kramer MB & Wong GY. Ototoxicity of High-Dose Cisplatin by Bolus Administration in Patients with Advanced Cancers and Normal Hearing. Laryngoscope 1988;98:858-863.
14. Bensadon RL. Estudo Clínico e Audiológico da Ototoxicidade da Cisplatina. Comparação entre os Exames de Audiometria Tonal Convencional, Audiometria de Altas Freqüências e Emissões Otoacústicas. [Tese Doutorado]. Faculdade de Medicina. Universidade de São Paulo, 1998.
15. Strauss M, Towfighi J, Lord S, Lipton A, Harvey HA & Brown B. Cis-platinum Ototoxicity: Clinical Experience and Temporal Bone Histopathology. Laryngoscope 1983;93:1554-1559.
16. Skinner B, Pearson ADJ, Amineddine DB, Mathias DB & Craft AW. Ototocixity of Cisplatinum in Children and Adolescents. Br J Cancer 1990;61:927-31.
17. Park KR. The Utility of Acoustic Reflex Threshold and Other Conventional Audiologic Tests for Monitoring Cisplatin Ototoxicity in the Pediatric Population. Ear Hear 1996;17:107-115.
18. Fausti SA, Henry JA, Helt WE, Phillips DS, Frey RH, Noffsinger D, Larson VD & Fowler CG. An Individualized, Sensitive Frequency Range for Early Detection of Ototoxicity. Ear Hear 1999;20:497-505.
19. Cevette M J, Drew D, Webb T & Marion MS. Cisplatina Ototoxicity, Increased DPOAE Amplitudes, and Magnesium Deficiency. J Am Acad Audiol 2000;11:323-329.
20. Allen GC, Tiu C, Koike K, Ritchey K, Kurs-Lasky M & Wax MK. Transient-Evoked Otoacoustic Emissions in Children After Cisplatin Chemotherapy. Otolaryngol Head Neck Surg 1998;118 (5):584-588.
21. Durrant JD, Furman JM & Carr B. DPOAE in Monitoring of Cisplatin Ototoxicity, 1997. Disponível em: URL:HTTP://www.ausp.memphis.edu/ierasg/ abstract/durrant.txt.
22. Biró K, Baki M, Büki B, Noszek L & Jókúti L. Detection of Early Ototoxic Effect in Testicular Cancer Patients Treated with Cisplatin by Transiently Evoked Otoacoustic Emission: a Pilot Study. Oncology 1997;54:387-399.
23. Ress BD, Sridhar KS, Balkany TJ, Waxman GM, Stagner BB & Lonsbury-Martin BL. Effects of cis-platinum Chemotherapy on Otoacustic Emissions: The Development of na Objective Screening Protocol. Otolaryngol Head Neck Surg 1999;121:693-701.
24. Berg AL, Spitzer JB & Garvin JH. Ototoxicity Impact of Cisplatin in Pediatric Oncology Patients. Laryngoscope 1999;109:1806-1814.
25. Baum ES, Gaynon P, Greenberg L, Krivit W & Hammond D. Phase II Study of cis-Dichlorodiammineplatinum (II) in Childhood Osteosarcoma: Children's Cancer Study Group Report. Cancer Treat Rep 1979;63 (9-10):1621-1627.